ArticleBMC cancer2018

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.

Catja Freiburghaus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.